Lawrence Eichenfield, MD, a board-certified dermatologist at the UC San Diego School of Medicine, discusses findings from the pediatric TRuE-AD3 trial evaluating topical ruxolitinib, a Janus kinase (JAK) inhibitor, for the treatment of atopic dermatitis in children aged 2–11 years. This vehicle-controlled study, which utilized a 2:1 randomization design, demonstrated significant efficacy of ruxolitinib, with approximately 56.5% of patients achieving treatment success compared to 11% in the vehicle group.
Topics Covered
- Mechanism and approval of topical ruxolitinib
- Trial design and efficacy and safety findings
- Real-world application and safety data
Explore Related Resources
